Developmental therapeutics program at the NCI: molecular target and drug discovery process (Q34605253)

3 August 2017

1 reference

title

Developmental therapeutics program at the NCI: molecular target and drug discovery process (English)

1 reference

3 August 2017

1 reference

Monga M

1 reference

3 August 2017

Sausville EA

series ordinal

1 reference

3 August 2017

language of work or name

1 reference

1 April 2002

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

520-526

1 reference

Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402464

7 January 2021

Selection of molecular fragment features for structure-activity studies in antitumor screening

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402464

7 January 2021

In vivo cultivation of tumor cells in hollow fibers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402464

7 January 2021

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402464

7 January 2021

Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402464

7 January 2021

Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402464

7 January 2021

An information-intensive approach to the molecular pharmacology of cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402464

7 January 2021

A gene expression database for the molecular pharmacology of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402464

7 January 2021

Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402464

7 January 2021

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402464

7 January 2021

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402464

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2402464

1 reference

Dimensions Publication ID

3 August 2017

1043215644

0 references

1 reference